Veeva Systems -CL

Veeva Systems provides software that helps pharmaceutical and biotechnology companies manage research, clinical trials, and regulatory work. Its subscription model creates stable, recurring revenue, and many customers stay with the company for years. Going forward, I will be watching whether Veeva can keep growing by winning new customers and expanding the use of its newer products.

$Phillip Morris(PM.US)

Philip Morris International: A Smoke-Free Growth Story

Philip Morris International $Phillip Morris(PM.US) has transformed itself from a traditional cigarette company into a global leader in reduced-risk nicotine products. In 2026, heated tobacco products led by IQOS, together with ZYN nicotine pouches and VEEV e-vapor, accounted for a growing share of revenue and profit. Higher-margin smoke-free products continue to drive earnings growth, while the combustible cigarette business remains a strong source of cash flow.

Compared with Altria, Philip Morris enjoys broader international exposure, stronger revenue growth and a more diversified portfolio of reduced-risk products. Altria continues to generate attractive cash flow and dividends but remains heavily dependent on the mature U.S. cigarette market, limiting its long-term growth prospects.

From a valuation perspective, Philip Morris trades at a premium to its peers, reflecting investor confidence in its smoke-free transition. Technically, the long-term trend remains bullish with higher highs and higher lows. For investors looking to initiate a position, the US$180–185 region represents the first area of technical support, while a deeper correction towards US$170–175 could provide a more attractive long-term entry if broader market weakness emerges. On the upside, the US$205–210 range is likely to act as a key resistance zone where profit-taking may increase. Long-term investors may consider accumulating on pullbacks towards support levels, while options investors may find opportunities selling cash-secured puts near support or covered calls as the stock approaches resistance, allowing premium income while maintaining a disciplined risk-reward profile.

Disclaimer: This article is for educational purposes only and should not be considered financial advice.

$Veeva Systems -CL(VEEV.US)

Veeva Systems $Veeva Systems -CL(VEEV.US): The AI Winner Built on Trust, Not Just Software

While many SaaS vendors compete on productivity, Veeva competes on regulatory trust. Serving the pharmaceutical and life sciences industry, its software is deeply embedded into clinical, regulatory and quality workflows where data integrity, audit trails and GxP compliance are mandatory. Replacing Veeva is far more complex than switching a CRM, creating exceptionally high customer stickiness with gross revenue retention consistently around mid-to-high 90% and subscription gross margins near 87%. (⁠ir.veeva.com)

FY2026 revenue climbed 16% to US$3.20 billion, while operating income surged 33% to US$916 million, highlighting both growth and expanding profitability. Falcon, Veeva’s new agentic AI platform, extends beyond copilots by automating regulated clinical, regulatory and safety workflows while preserving compliance—an advantage generic AI platforms struggle to replicate. (⁠ir.veeva.com)

Technically, VEEV remains in a long-term uptrend but has become extended after its AI-driven rally. Investors should watch for support near the 50-day moving average before initiating new positions.

Key risks include slower Falcon monetisation, pharmaceutical R&D spending cuts, increasing competition from Salesforce and IQVIA, and premium valuation leaving little room for execution missteps. For option traders, cash-secured puts after meaningful pullbacks may offer a better risk-reward profile than chasing momentum.

Disclaimer: This article is for educational and informational purposes only and should not be construed as financial or investment advice. Always conduct your own due diligence before making any investment decisions.

$Veeva Systems -CL(VEEV.US) | Veeva Systems (VEEV) Analyst Price Target Updates

📢 Companies Reporting Earnings Next Week

🚨 $SPY S&P500 REBALANCING

Michael Burry just went long on three beaten-down software stocks